Oppenheimer Downgrades Biogen (BIIB) to Perform
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.15 -0.32%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
After the close, Oppenheimer downgraded Biogen (NASDAQ: BIIB) from Outperform to Perform.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $152.94 yesterday.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $152.94 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Seaport Global Securities Downgrades JetBlue Airways (JBLU) to Neutral
- Deutsche Bank Downgrades Workday (WDAY) to Hold
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
